Brief Inhibitory Control Training for Overweight Teens

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This proof-of-concept study tests daily inhibitory control training delivered via a smartphone app to adolescents with overweight or obesity. It aims to assess whether the training is feasible and acceptable in daily life and whether it changes food-related self-control and eating regulation. Participants complete questionnaires and cognitive tasks, receive short nutrition education, and engage in three weeks of daily brain games. The study is conducted at George Mason University and focuses on a mobile-based intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 14-17 years old
* Have overweight or obesity (BMI-z≥85th percentile)
* Have a smartphone
* Can read and speak English
* Interest in improving one's diet.

Exclusion Criteria:

* Not currently in eating disorder or weight loss treatment or receiving pharmacological/surgical treatment for obesity in the past four weeks
* Not meeting criteria for atypical anorexia nervosa or bulimia nervosa

Where it's running

• George Mason University
  Fairfax, Virginia, United States Recruiting

Study contacts

• Principal investigator: Tyler Mason, PhD — George Mason University
• Study coordinator: Tyler Mason, PhD
• Email: tmason24@gmu.edu
• Phone: 703-993-1000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Berobenatide in adults with sleep apnea and obesity who don’t use a PAP machine

  This study tests berobenatide versus placebo in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity who are not using PAP therapy.

  Recruiting at 3 sites Phase 3 Pfizer · Cullman, Alabama and 3 other locations · NCT07881757

• Berobenatide: how it enters the blood after different delivery methods in adults with overweight or obesity

  This study tests a single dose of Berobenatide to see how it behaves in the body when given in different delivery forms to adults with overweight or obesity.

  Recruiting Phase 1 Pfizer · Anaheim, California · NCT07876531

• Switching to a monthly dose of Berobenatide to help keep weight off after weight loss with semaglutide or tirzepatide

  This study tests whether switching to a monthly berobenatide shot can help adults who have overweight or obesity and have already lost weight using semaglutide or tirzepatide to keep the weight off.

  Recruiting at 18 sites Phase 3 Pfizer · Birmingham, Alabama and 25 other locations · NCT07845500

• Berobenatide in adults with sleep apnea and obesity using a PAP machine

  This study tests berobenatide vs. placebo in adults with moderate to severe obstructive sleep apnea and overweight/obesity who use a PAP device.

  Recruiting at 6 sites Phase 3 Pfizer · Cullman, Alabama and 7 other locations · NCT07823608

• Body- or Mind-based regulation in women with overweight or obesity

  This study tests whether a body-based regulation program or a mind-based regulation program helps women with overweight or obesity improve heart rate regulation and emotional eating.

  Recruiting Pamukkale University · Denizli · NCT07738263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.